We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-21.96%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$203M
AUM Growth
-$73.1M
Cap. Flow
-$10.1M
Cap. Flow %
-4.97%
Top 10 Hldgs %
89.27%
Holding
22
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$8.15M
2
OBSV
ObsEva SA Ordinary Shares
OBSV
+$1.79M
3
RCOR
Renovacor, Inc.
RCOR
+$150K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
1
Arvinas
ARVN
$572M
$86.8M 42.77%
1,289,521
– –
RLYB icon
2
Rallybio
RLYB
$85.8M
$16.1M 7.92%
287,700
– –
HARP
3
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$15.7M 7.73%
315,670
– –
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.68B
$15.1M 7.43%
1,553,661
– –
DCPH
5
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.2M 5.53%
1,209,571
– –
DICE
6
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$10.7M 5.25%
556,693
– –
PASG icon
7
Passage Bio
PASG
$14.1M
$7.74M 3.82%
124,896
– –
APTX
8
DELISTED
Aptinyx Inc. Common Stock
APTX
$7.47M 3.68%
3,290,079
– –
CMRX
9
DELISTED
Chimerix, Inc.
CMRX
$5.61M 2.76%
1,224,600
– –
ALEC icon
10
Alector
ALEC
$198M
$4.84M 2.38%
339,569
– –
SRRA
11
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.02M 1.98%
125,511
-284,100
-69% -$8.15M
COGT icon
12
Cogent Biosciences
COGT
$7.24B
$3.76M 1.85%
501,530
– –
AMYT
13
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$3.72M 1.83%
449,737
– –
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.92B
$3.1M 1.53%
141,000
– –
RCOR
15
DELISTED
Renovacor, Inc.
RCOR
$2.85M 1.41%
672,288
-25,148
-4% -$150K
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.83M 0.9%
946,423
– –
PDSB icon
17
PDS Biotechnology
PDSB
$43.4M
$726K 0.36%
117,242
– –
XFOR icon
18
X4 Pharmaceuticals
XFOR
$438M
$586K 0.29%
11,167
– –
ITRM
19
DELISTED
Iterum Therapeutics
ITRM
$517K 0.25%
97,087
– –
TECX
20
Tectonic Therapeutic
TECX
$585M
$417K 0.21%
26,296
– –
ADXN
21
Addex Therapeutics
ADXN
$7.34M
$254K 0.13%
2,500
– –
OBSV
22
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-900,501
Closed -$1.79M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q1 2022 Portfolio in Review

As of Q1 2022, New Leaf Venture Partners held 22 positions worth $203M, down 26% from $276M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

New Leaf Venture Partners withdrew a net $10.1M in Q1 2022, closing 1 position and reducing 2 holdings. Its most notable exit was ObsEva SA Ordinary Shares, an estimated $1.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • New Leaf Venture Partners's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $8.15M.
  • New Leaf Venture Partners fully exited ObsEva SA Ordinary Shares in Q1 2022, selling an estimated $1.79M.
  • New Leaf Venture Partners's ten largest holdings make up 89% of its $203M portfolio in Q1 2022.
  • New Leaf Venture Partners opened 0 new positions and closed 1 in Q1 2022.
  • New Leaf Venture Partners's portfolio value fell 26% quarter-over-quarter to $203M.

Based on New Leaf Venture Partners's 13F filing for Q1 2022, filed 6 May 2022.